N. Bergasa, D. Alling, T. Talbot
Sep 1, 1999
Citations
2
Influential Citations
146
Citations
Quality indicators
Journal
Journal of the American Academy of Dermatology
Abstract
BACKGROUND Intravenous naloxone frequently ameliorates the pruritus of cholestasis, but its low oral bioavailability precludes its use as a long-term therapy. Nalmefene is an orally bioavailable opiate antagonist. OBJECTIVE We assessed the efficacy of oral nalmefene in ameliorating the pruritus of cholestasis. METHODS In a prospective controlled study conducted in a tertiary referral hospital, 11 patients with generalized pruritus complicating chronic liver disease were randomized to receive either nalmefene or placebo in a double-blinded fashion for 2-month periods. Scratching activity was measured continuously for 24-hour periods at baseline and at the end of each treatment period. RESULTS Data on 8 patients who received at least 1 course of nalmefene were available for comparison with corresponding control data, which consisted of observations obtained during a course of placebo and/or at baseline. Nalmefene therapy was associated with a 75% reduction in the geometric mean hourly scratching activity (P <.01) and a decrease in the mean of a visual analogue score of the perception of pruritus in all 8 patients (mean decrease 77%, P <.01). CONCLUSION Oral administration of nalmefene can ameliorate pruritus complicating chronic liver disease.